2 Defensive Healthcare Stocks to Buy Right Now

Two healthcare stocks — Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) — are recommended as defensive buys: Abbott for its diversified business mix (medical devices, diagnostics, nutrition, established pharma) and status as a Dividend King with 50+ years of consecutive increases; Intuitive for its durable moat around Da Vinci systems and recurring revenue from instruments/accessories. The article flags macro risks (uncertainty over AI revenue upside, unclear pace of interest-rate cuts, and the war in Iran) that support adding non-cyclical, dividend-paying and recurring-revenue healthcare positions to weather market volatility.

Analysis

Hospitals facing higher-for-longer rates create a bifurcated outcome for medtech: capital purchases (high-ticket systems) will be lumpy for the next 6–18 months while service and consumable revenue tied to installed bases becomes a larger, more predictable cash flow line. That dynamic magnifies optionality for companies with recurring consumable economics — near-term top-line growth can lag, but margin and FCF profiles are more resilient and easier to finance via leasing or annuity structures.

For a diversified healthcare name with a steady capital-return policy, investor flows will likely pivot into yield and buyback stories during bouts of risk aversion; however, this crowding compresses near-term multiple expansion and raises sensitivity to any surprise reimbursement or recall headlines. FX, supply-chain concentration in Asia, and regulatory headlines (FDA recalls, CMS reimbursement guidance) are underappreciated tail risks that can move multiples more than underlying organic trends over 3–12 months.

Robotic-surgery leaders sit on a multi-year secular adoption curve, but that optionality is vulnerable to competitor modular platforms and hospital procurement innovations (leasing, shared-service networks). Practically, the trade looks like owning the annuity-like attach revenue while limiting exposure to the lumpy, interest-rate-sensitive capital cycle; this argues for staggered, option-enabled exposure rather than a straight outright long in the current macro environment.

Key Decisions for Investors

• Core long ABT (3–5% NAV) — buy shares as a defensive yield anchor with a 12–36 month horizon; enhance yield by selling 9–12 month covered calls roughly 10–15% out-of-the-money to generate carry. Risk: 12% downside stop; Reward: 10–20% total return target including income, fungible into a long-term hold if macro softens.
• Tactical ISRG exposure (1–2% NAV) — express secular upside via long-dated (18–36 month) call spreads to cap premium cost (buy lower strike / sell higher strike) and size to 1–2% NAV. Trade trigger: add on any >8–10% pullback or after two consecutive months of improved hospital capex data; objective: 2–4x uplift on premium if instrument/attach growth re-accelerates, max loss = premium paid.
• Relative play: long ISRG / short a broad capex-exposed medtech (equal notional, 6–18 month horizon) — isolates robotics secular attach vs cyclical hospital capital spending. Set reversion exit if spread narrows by 30% or widen by 50% for profit taking; risk managed by equal notional sizing and 10% stop on either leg.
• Event hedge (0.5–1% NAV) — buy 3–6 month out-of-the-money puts on the core long (ABT or ISRG) to protect against abrupt regulatory/reimbursement shocks or a rapid risk-off that hits defensives. Cost is insurance; use as a rolling hedge and trim once premiums fall below 0.5% NAV per annum.